Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: A case report

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 6, 2006, Pages 645-648

  Cay, H F ^a   Gungor, H A ^a   Sezer, I ^a   Kacar, C ^a   Balci, N ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Ankylosing spondylitis; Anti tumour necrosis factor alpha drugs; Transverse myelitis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CASE REPORT; CERVICAL SPINAL CORD INJURY; DEMYELINATION; HUMAN; MALE; MYELITIS; TREATMENT OUTCOME;

ADULT; CERVICAL VERTEBRAE; HUMANS; IMMUNOGLOBULIN G; MALE; MYELITIS, TRANSVERSE; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751383959     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00779.x     Document Type: Article

References (15)

1. Harzheim M, Schlegel U, Urbach H et al. (2004) Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients. Journal of the Neurological Sciences, 217, 217-223.
2. Brinar VV, Habek M, Brinar M et al. (2006) The differential diagnosis of acute transverse myelitis. Clinical Neurology and Neurosurgery, 108, 278-283.
3. Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology, 57, 1885-1888.
4. Enayati PJ, Papadakis KA (2005) Association of antitumor necrosis factor therapy with the development of multiple sclerosis. Journal of Clinical Gastroenterology, 39, 303-306.
5. Richez C, Blanco P, Lagueny A et al. (2005) Neuropathy resembling CIPD in patients receiving tumor necrosis factor α blockers. Neurology, 64, 1468-1470.
6. van Oosten BW, Barkhof F, Boringa JB et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology, 47, 1531-1534.
7. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology, 53, 457-465.
8. Mohan N, Edwards ET, Cupps TR et al. (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis and Rheumatism, 44, 2862-2869.
9. Magnano MD, Robinson WH, Genovese MC (2004) Demyelination and inhibition of tumor necrosis factor (TNF). Clinical and Experimental Rheumatology, 22(Suppl. 35), S134-S140.
10. Robinson WH, Genovese MC, Moreland LW (2001) Demyelination and neurologic events reported in association with tumour necrosis factor α antagonism. By what mechanisms could tumor necrosis factor α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis. Arthritis and Rheumatism, 44, 1977-1983.
11. Miller FW, Hess EV, Clauw DJ et al. (2000) Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis and Rheumatism, 43, 243-249.
12. Dönmez B, Özakbas S, Öktem MA et al. (2004) HLA genotypes in Turkish patients with myasthenia gravis: comparison with multiple sclerosis patients on the basis of clinical subtypes and demographic features. Human Immunology, 65, 752-757.
13. Transverse Myelitis Consortium Working Group (2005) Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology, 59, 499-505.
14. Bellesi M et al. (2006) CNS demyelination during anti-tumor necrosis alpha therapy. Journal of Neurology, 253, 668-669.
15. Al Saieg N, Luzar MJ (2006) Etanercept induced multiple sclerosis and transverse myelitis. Journal of Rheumatology, 33, 1202.